Dáil Éireann Debate, Tuesday - 7 March 2017
628. Deputy Thomas P. Broughan asked the Minister for Health his views on Gardasil; if treatment plans have been worked out for the cohort of girls affected by adverse reactions; and if he will make a statement on the matter. [12000/17]
View answerThe immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). NIAC is a committee of the Royal College of Physicians of Ireland comprising of experts in a number of specialties including infectious diseases, paediatrics and public health. The committee's recommendations are informed by public health advice and international best practice. The Health Products Regulatory Authority (HPRA) and the European Medicines Agency (EMA) in Europe continually monitor adverse events to vaccination. All relevant and appropriate information is taken into account when deciding to make changes to the State's immunisation programmes.
Each year in Ireland around 300 women are diagnosed with cervical cancer. The HPV vaccine protects against two high risk types of HPV (16 & 18) that cause 73% of all cervical cancers. Vaccinated women and girls will still be at risk from other high risk types of HPV that can cause cervical cancer and will therefore need to continue to have regular cervical smear tests. NIAC recommended that the human papillomavirus (HPV) vaccine be given to all girls aged 12-13 in 2009 and in September 2010 the HPV vaccination programme was introduced for all girls in first year of second level schools.
Gardasil is the HPV vaccine used in Ireland in the context of the HSE schools immunisation programme. In Ireland more than 660,000 doses of Gardasil have been administered and almost 250,000 girls have been vaccinated against HPV. Over 205 million doses of the HPV vaccine Gardasil have been distributed worldwide, either as part of national immunisation programmes or by private doctors. Gardasil is currently used in over 25 European countries, the United States, Canada, Australia and New Zealand.
I am aware of claims of an association between HPV vaccination and a number of conditions experienced by a group of young women. An illness that occurs around the time a vaccine is given and is already known to be common in adolescence does not imply the vaccine caused the problem. It appears that some girls first suffered symptoms around the time they received the HPV vaccine, and understandably some parents have connected the vaccine to their daughter’s condition. It is important to reassure people that anyone who is suffering ill health is eligible to seek medical attention, and to access appropriate health and social care services, irrespective of the cause of their symptoms. The individual nature of the needs of some children may require access to specialist services and the HSE are currently working to put in place a clinical care pathway appropriate to the medical needs of this group. As there is no scientific evidence that the vaccine causes long term illnesses, the HPV vaccine cannot be held responsible for these illnesses.
The focus for the HPV programme in 2017 is to counter misinformation in relation to the safety of the HPV vaccine, and to increase the uptake rate in girls as part of the schools immunisation programme. The benefits of HPV vaccines outweigh the known side effects. The safety of these vaccines, as with all medicines, will continue to be carefully monitored and will take into account any future new evidence of side effects that becomes available. I encourage the parents of all eligible girls to ensure that their daughters receive this important cancer-preventing vaccine.
